Media.Player

Modifying immune response through

技術優勢

Potentially enhances T cell response in a wider group of cancer patients Improves the understanding of the role of CTLA-4 in auto immune disease and opens up new approaches to treating diseases such as diabetes

詳細技術說明

CTLA-4 is part of a complicated system that controls T cell activation. When CD28, a molecule expressed on T cells, binds to either CD80 or CD86 expressed on other cells it induces T cell activation. CTLA-4 also binds to CD80 and CD86 and acts to inhibit T cell activation. A soluble version of CTLA-4 could prevent T cell activation by blocking CD80 and CD86 from binding to CD28. In addition, soluble CTLA-4 is released by T cells and occurs naturally in humans. It is elevated in autoimmune diseases however it is not clear how it functions. It would be expected to inhibit T cell activation. Workers at the University have produced a new form of soluble CTLA-4 (sCTLA-4) that exists as a monomeric protein in contrast to CTLA-4 Ig. Surprisingly we have found that soluble CTLA-4 can boost immune responses.

*Abstract

CTLA-4 is a protein and is one of the most important immune regulators, with potential for use in human cancer therapy. However commercial antibodies that block CTLA-4, and activate the immune system, are effective in only a small percentage of patients, however, in patients where the antibody is effective, massive tumour regression is seen.

*Principal Investigation

Name: Prof. David Sansom

Department:

附加資料

Inventor: QURESHI, Omar Saleem | SANSOM, David Michael
Priority Number: WO2012127240A3
IPC Current: A61K003800 | G01N003350
Assignee Applicant: The University of Birmingham
Title: IMMUNE ASSAY | ESSAI IMMUNOLOGIQUE
Usefulness: IMMUNE ASSAY | ESSAI IMMUNOLOGIQUE

主要類別

生物醫學

細分類別

生物工程

國家/地區

美國